Enterprise Value to EBITDA Ratio: Viracta (VIRX)
This price chart illustrates the EV/EBITDA multiple, which currently stands at . Viracta Therapeutics (VIRX) possesses a unique enzyme activation technology for lymphoma therapy, supported by favorable contracts and high profitability. The business serves as a defensive asset, as its internal development cycle remains independent of global crises. Efficiency is enhanced through the robotization of biomarker analysis, which minimizes manual labor.
viracta.com (VIRX) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Viracta Therapeutics|VIRX - Long-Term Debt to Equity|Short-Term Debt to Capital Viracta Therapeutics, Inc.|VIRX - Company Total Debt Obligations|Debt to Book Capitalization Ratio Viracta Therapeutics, Inc.|VIRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Viracta Therapeutics|Quick Ratio viracta.com
- business earnings and investment ratios data:
VIRX - Net Income|Future Profit Viracta Therapeutics|VIRX - Market Price to Net Income Ratio|Forward P/E Multiple Viracta Therapeutics, Inc.|VIRX - PEG Multiple|Enterprise Value to EBITDA Ratio Viracta Therapeutics, Inc.|VIRX - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Viracta Therapeutics|VIRX - Earnings per share for the last four quarters|Quarterly EPS earnings growth viracta.com|VIRX - Earnings per share increase in current year|Earnings growth forecast for next year Viracta Therapeutics
- company sales and revenue statistics:
Comprehensive company analysis:VIRX (Viracta)
Viracta Therapeutics (VIRX) holds exclusive patents in lymphoma therapy that create a high barrier to entry, ensuring stable operating income. The EV/EBITDA multiple relates the total enterprise value, including debt, to this profitability before taxes, depreciation, and amortization. This indicator determines the payback period of assets; therefore, tracking changes in the EV/EBITDA value over time allows for the timely detection of company overvaluation relative to its actual efficiency.
Key competitors
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to EBITDA Ratio ERAS (Erasca, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DCTH (delcath.com)|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Aura Biosciences Inc (AURA)|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ARAY (Accuray, Inc.)|SLS: EV/EBITDA Multiple|actuatetherapeutics.com (ACTU) - EV/EBITDA Multiple|CTOR (Citius Oncology) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio TuHURA (HURA)|Enterprise Value to EBITDA Ratio TARA (Protara)|Enterprise Value to Operating Income Before Depreciation Ratio FATE|EV/EBITDA Multiple WHWK (Aadi Bioscience)|EV/EBITDA Multiple TScan Therapeutics Inc TCRX|CSBR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc.)|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OSTX: Enterprise Value to Operating Income Before Depreciation Ratio|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|ARTV: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANL|VERU - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|Business Value to Operating Income Before Depreciation XLO|Enochian BioSciences - EV/EBITDA Multiple|MURA - EV/EBITDA Multiple|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OKUR (OnKure Therapeutics)|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|Company Value to EBITDA Curis Corp CRIS|Enterprise Value to EBITDA Ratio APLM (Apollomics, Inc.)|EV/EBITDA Multiple tharimmune.com (THAR)|Advanced Biomed - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio GNPX (Genprex Inc.)|Calidi Bio - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio sunshinebiopharma.com SBFM|XBIO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio salariuspharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Purple Biotech Ltd.|AON (AONC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BGNE (BeOne Medicines)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CKPT (Checkpoint Therapeutics Inc)|EV/EBITDA Multiple ELEV (Elevation Oncology)|Total Company Value to Operating Income Before Depreciation Ratio iCAD Inc. (ICAD)|IKNA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation NTBL (Notable Labs Ltd)|MOR (MorphoSys Corp) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation NAYA|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
